EDIT vs. ADVM, CLLS, RGNX, SGMO, BLUE, NMRA, VIR, TARS, BCRX, and CGEM
Should you be buying Editas Medicine stock or one of its competitors? The main competitors of Editas Medicine include Adverum Biotechnologies (ADVM), Cellectis (CLLS), REGENXBIO (RGNX), Sangamo Therapeutics (SGMO), bluebird bio (BLUE), Neumora Therapeutics (NMRA), Vir Biotechnology (VIR), Tarsus Pharmaceuticals (TARS), BioCryst Pharmaceuticals (BCRX), and Cullinan Therapeutics (CGEM). These companies are all part of the "biological products, except diagnostic" industry.
Editas Medicine (NASDAQ:EDIT) and Adverum Biotechnologies (NASDAQ:ADVM) are both small-cap medical companies, but which is the better business? We will contrast the two businesses based on the strength of their community ranking, risk, media sentiment, valuation, dividends, institutional ownership, analyst recommendations, earnings and profitability.
Adverum Biotechnologies has lower revenue, but higher earnings than Editas Medicine. Editas Medicine is trading at a lower price-to-earnings ratio than Adverum Biotechnologies, indicating that it is currently the more affordable of the two stocks.
Adverum Biotechnologies has a net margin of 0.00% compared to Editas Medicine's net margin of -239.36%. Editas Medicine's return on equity of -47.34% beat Adverum Biotechnologies' return on equity.
In the previous week, Editas Medicine had 2 more articles in the media than Adverum Biotechnologies. MarketBeat recorded 9 mentions for Editas Medicine and 7 mentions for Adverum Biotechnologies. Adverum Biotechnologies' average media sentiment score of 1.02 beat Editas Medicine's score of 0.21 indicating that Adverum Biotechnologies is being referred to more favorably in the news media.
Editas Medicine has a beta of 2.09, suggesting that its stock price is 109% more volatile than the S&P 500. Comparatively, Adverum Biotechnologies has a beta of 0.89, suggesting that its stock price is 11% less volatile than the S&P 500.
Adverum Biotechnologies received 62 more outperform votes than Editas Medicine when rated by MarketBeat users. Likewise, 60.87% of users gave Adverum Biotechnologies an outperform vote while only 53.74% of users gave Editas Medicine an outperform vote.
Editas Medicine currently has a consensus target price of $13.27, indicating a potential upside of 155.24%. Adverum Biotechnologies has a consensus target price of $29.00, indicating a potential upside of 266.16%. Given Adverum Biotechnologies' stronger consensus rating and higher possible upside, analysts plainly believe Adverum Biotechnologies is more favorable than Editas Medicine.
71.9% of Editas Medicine shares are held by institutional investors. Comparatively, 48.2% of Adverum Biotechnologies shares are held by institutional investors. 1.9% of Editas Medicine shares are held by company insiders. Comparatively, 4.2% of Adverum Biotechnologies shares are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth.
Summary
Adverum Biotechnologies beats Editas Medicine on 10 of the 18 factors compared between the two stocks.
Get Editas Medicine News Delivered to You Automatically
Sign up to receive the latest news and ratings for EDIT and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding EDIT and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Editas Medicine Competitors List
Related Companies and Tools
